[Montelukast in treatment mild chronic asthma]. / Montelukast w leczeniu astmy przewleklej lagodnej u dzieci.

UNLABELLED: The efficacy of montelukast, a leukotriene receptor antagonist, in treatment of mild asthma was evaluated. METHODS: Thirty children aged 6 to 14 years with mild persistent asthma (asthma history more than 12 months and > or = 15% FEV1 improvement after inhaled beta 2-agonist in the past, good control of asthma with inhaled cromolyn or budesonide in the last three months) were enrolled. The study included three periods (2 week's each): washout, placebo, and montelukast. Asthma symptoms score (range 0-5) and PEF were estimated twice daily by children. Spirometric parameters FEV1 and MEF50 were measured during three consecutive visits: on the day of study inclusion, on the last day of the placebo and montelukast period. RESULTS: The mean value of asthma symptoms score was significantly lower during the montelukast period in comparison with placebo (p = 0.038). The mean PEF values were significantly higher during the montelukast vs. placebo period (p = 0.0091). Moreover, in the montelukast period, the mean PEF values in the second week were significantly higher than those in the first week (p = 0.003). The mean FEV1 predictive value in the last day of the montelukast period was higher, though not significantly, than on the day of study inclusion and on the last day of the placebo period. A similar change in mean MEF50 values was observed. CONCLUSION: In children aged 6-14 years with mild persistent asthma, montelukast treatment significantly diminishes asthma symptoms and increases mean PEF values comparing to placebo.

[Bronchial asthma: do boys or girls have the highest incidence?]. / Astma oskrzelowa: kto czesciej choruje dziewczeta czy chlopcy?.

The aim of the study was to assess the gender related prevalence of asthma and asthma symptoms in schoolchildren. The survey was performed using standardized ISAAC questionnaire in two age groups: 6-7 yr. (n = 2281; girls 49.7%) and 13-14 yr. (n = 4849; girls 49.8%). It was revealed that in older group the prevalence of ever diagnosed asthma was lower in girls than in boys (2.0% versus 3.3%; odds ratio [OR] = 0.58; p = 0.004). But the prevalence of symptoms: wheeze ever (OR = 1.16; p = 0.056), current wheeze (last 12 mo) (OR = 1.26; p = 0.029), current exercise wheeze (OR = 1.40; p = 0.0008), current night cough (OR = 1.67; p = 0.0001) were higher in girls than in boys. However, in younger group of schoolchildren the prevalence of ever diagnosed asthma and asthma symptoms were higher in boys (5.1% male versus 3.5% female). The girls in comparison to boys revealed lower risk of ever asthma diagnosis (OR = 0.66; p = 0.056) and symptoms: wheeze ever (OR = 0.63; p = 0.0001), current wheeze (OR = 0.69; p = 0.003), current exercise wheeze (OR = 0.59; p = 0.008) and current night cough (OR = 0.70; p = 0.0003).

Congenital stridor.

Fifty-two infants and children with stridor were examined. The median age was 5 months and the boy/girl ratio was 2:1. Fiberoptic bronchoscopy was performed when other diagnostic methods had failed to establish the origin of stridor. The most common cause of stridor was laryngomalacia, which was found in 34 children (65%). The most common form of laryngomalacia was due to large, floppy arytenoid cartilages; this was observed twice as often as other forms of laryngomalacia and boys suffered from this abnormality more than twice as often as girls. Children with laryngomalacia had significant weight (24%) and height (8%) deficits in comparison with the normal healthy population (P < 0.001). In all but four patients with laryngomalacia, blood gases were within normal limits. In 18 children (35%) stridor was not caused by laryngomalacia. This group showed significant etiologic heterogeneity. However, identification of the cause of stridor in these patients is important because specific treatment can be offered and prognosis depends on the type and cause of the anatomical and functional abnormality present.

Wiskott-Aldrich syndrome. A case report.

This paper presents a report on a child with Wiskott-Aldrich syndrome. The clinical picture and laboratory findings are characteristic of this disease. The prevailing symptoms have included recurrent respiratory and alimentary tract infections, seborrhic dermatitis-type skin lesions, and thrombocytopenia. Humoral and cellular immunological disturbances have been noted, and the pedigree pattern is very characteristic.